1
|
Ganesan S, Mathews V, Vyas N. Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough? Int J Cancer 2021; 150:1401-1411. [PMID: 34921734 DOI: 10.1002/ijc.33908] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Revised: 12/09/2021] [Accepted: 12/10/2021] [Indexed: 12/18/2022]
Abstract
Acute myeloid leukemia (AMLs), as the name suggests, often develop suddenly and are very progressive forms of cancer. Unlike in acute promyelocytic leukemia, a subtype of AML, the outcomes in most other AMLs remain poor. This is mainly attributed to the acquired drug resistance and lack of targeted therapy. Different studies across laboratories suggest that the cellular mechanisms to impart therapy resistance are often very dynamic and should be identified in a context-specific manner. Our review highlights the progress made so far in identifying the different cellular mechanisms of mutation-independent therapy resistance in AML. It reiterates that for more effective outcomes cancer therapies should acquire a more tailored approach where the protective interactions between the cancer cells and their niches are identified and targeted.
Collapse
Affiliation(s)
- Saravanan Ganesan
- Department of Haematology, Christian Medical College, Vellore, India
| | - Vikram Mathews
- Department of Haematology, Christian Medical College, Vellore, India
| | - Neha Vyas
- Division of Molecular Medicine, St. John's Research Institute, SJNAHS, Bengaluru, India
| |
Collapse
|
2
|
miR-194-5p/BCLAF1 deregulation in AML tumorigenesis. Leukemia 2017; 31:2315-2325. [PMID: 28216661 PMCID: PMC5668498 DOI: 10.1038/leu.2017.64] [Citation(s) in RCA: 54] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Revised: 12/28/2016] [Accepted: 02/14/2017] [Indexed: 02/07/2023]
Abstract
Deregulation of epigenetic mechanisms, including microRNA, contributes to leukemogenesis and drug resistance by interfering with cancer-specific molecular pathways. Here, we show that the balance between miR-194-5p and its newly discovered target BCL2-associated transcription factor 1 (BCLAF1) regulates differentiation and survival of normal hematopoietic progenitors. In acute myeloid leukemias this balance is perturbed, locking cells into an immature, potentially ‘immortal’ state. Enhanced expression of miR-194-5p by treatment with the histone deacetylase inhibitor SAHA or by exogenous miR-194-5p expression re-sensitizes cells to differentiation and apoptosis by inducing BCLAF1 to shuttle between nucleus and cytosol. miR-194-5p/BCLAF1 balance was found commonly deregulated in 60 primary acute myeloid leukemia patients and was largely restored by ex vivo SAHA treatment. Our findings link treatment responsiveness to re-instatement of miR-194-5p/BCLAF1 balance.
Collapse
|
3
|
Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G, Yang K. MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2015; 8:384-393. [PMID: 25755726 PMCID: PMC4348820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Accepted: 12/22/2014] [Indexed: 06/04/2023]
Abstract
MiR-130a has been demonstrated to play important roles in many types of cancers. Nevertheless, its biological function in breast cancer remains largely unknown. In this study, we found that the expression level of miR-130a was down-regulated in breast cancer tissues and cells. Overexpression of miR-130a was able to inhibit cell proliferation, invasion and migration in MCF7 and MDA-MB-435 cells. With the bioinformatics analysis, we further identified that RAB5A was a directly target of miR-130a, and its mRNA and protein level was negatively regulated by miR-130a. Immunohistochemistry verified RAB5A was upregulated in breast cancer tissues. Therefore, the data reported here demonstrate that miR-130a is an important tumor suppressor in breast cancer, and imply that miR-130a/RAB5A axis have potential as therapeutic targets for breast cancer.
Collapse
Affiliation(s)
- Yuanqing Pan
- Institute of Medical Psychology, Evidence-Based Medicine Center, Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, School of Basic Medical SciencesLanzhou, Gansu, China
| | - Renjie Wang
- Department of Clinical Laboratory, Pingjin Hospital, Logistics College of Armed Police ForcesTianjin, China
| | - Fengwa Zhang
- Second Department of Gynaecology, Gansu Province People’s HospitalLanzhou, Gansu, China
| | - Yonglin Chen
- Department of Pathology, First Affiliated Hospital of Lanzhou UniversityLanzhou, Gansu, China
| | - Qingfang Lv
- Department of radiology, The Tumor Hospital of Gansu ProvinceLanzhou, Gansu, China
| | - Ge Long
- Evidence-Based Medicine Center, Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, School of Basic Medical SciencesLanzhou, Gansu, China
| | - Kehu Yang
- Evidence-Based Medicine Center, Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, School of Basic Medical SciencesLanzhou, Gansu, China
| |
Collapse
|
4
|
Miceli M, Bontempo P, Nebbioso A, Altucci L. Natural compounds in epigenetics: a current view. Food Chem Toxicol 2014; 73:71-83. [PMID: 25139119 DOI: 10.1016/j.fct.2014.08.005] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2014] [Revised: 08/06/2014] [Accepted: 08/08/2014] [Indexed: 01/03/2023]
Abstract
The successful treatment of many human diseases, including cancer, has come to be considered a major challenge, as patient response to therapy is difficult to predict. Recently, considerable efforts are being focused on the development of new tools to meet the growing demand for personalized medicine. With few exceptions, synthetic compounds have been unable to meet initial expectations for their clinical use. The last twenty years have been characterized by the failure of several drugs in advanced clinical development, possibly due to the insufficient understanding of molecular pathways underlying their mechanism of action. Although the biodiversity of compounds found in nature has been poorly explored until now, the field of naturally occurring drugs is rapidly expanding. Here, we review the current knowledge on the use of natural compounds with particular emphasis on those that display a chromatin remodeling effect coupled with anticancer action.
Collapse
Affiliation(s)
- Marco Miceli
- Dipartimento di Biochimica, Biofisica e Patologia Generale, Seconda Universita' di Napoli, Via L. De Crecchio 7, 80138 Napoli, Italy; Istituto di Genetica e Biofisica, Adriano Buzzati-Traverso, IGB, Via P. Castellino 111, 80131 Napoli, Italy
| | - Paola Bontempo
- Dipartimento di Biochimica, Biofisica e Patologia Generale, Seconda Universita' di Napoli, Via L. De Crecchio 7, 80138 Napoli, Italy
| | - Angela Nebbioso
- Dipartimento di Biochimica, Biofisica e Patologia Generale, Seconda Universita' di Napoli, Via L. De Crecchio 7, 80138 Napoli, Italy
| | - Lucia Altucci
- Dipartimento di Biochimica, Biofisica e Patologia Generale, Seconda Universita' di Napoli, Via L. De Crecchio 7, 80138 Napoli, Italy; Istituto di Genetica e Biofisica, Adriano Buzzati-Traverso, IGB, Via P. Castellino 111, 80131 Napoli, Italy.
| |
Collapse
|
5
|
Zhang J, Wu H, Li P, Zhao Y, Liu M, Tang H. NF-κB-modulated miR-130a targets TNF-α in cervical cancer cells. J Transl Med 2014; 12:155. [PMID: 24885472 PMCID: PMC4084577 DOI: 10.1186/1479-5876-12-155] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2013] [Accepted: 05/20/2014] [Indexed: 02/08/2023] Open
Abstract
Background Nuclear factor-κB (NF-κB) induces a variety of biological processes through transcriptional gene control whose products are components in various signaling pathways. MicroRNAs are a small endogenous non-coding RNAs that regulate gene expression and are involved in tumorigenesis. Using human cervical cancer cell lines, this study aimed to investigate whether NF-κB could regulate miR-130a expression and the functions and targets of miR-130a. Methods We used the HeLa and C33A cervical cancer cell lines that were transfected with NF-κB or miR-130a overexpression plasmids to evaluate their effects on cell growth. We utilized bioinformatics, a fluorescent reporter assay, qRT-PCR and Western blotting to identify downstream target genes. Results In HeLa and C33A cells, NF-κB and miR-130a overexpression promoted cell growth, but genetic knockdowns suppressed growth. TNF-α was identified as a target of miR-130a by binding in a 3’-untranslated region (3’UTR) EGFP reporter assay and by Western blot analysis. Furthermore, low TNF-α concentrations stimulated NF-κB activity and then induced miR-130a expression, and TNF-α overexpression rescued the effects of miR-130a on cervical cancer cells. Conclusions Our findings indicate that TNF-α can activate NF-κB activity, which can reduce miR-130a expression, and that miR-130a targets and downregulates TNF-α expression. Hence, we shed light on the negative feedback regulation of NF-κB/miR-130a/TNF-α/NF-κB in cervical cancer and may provide insight into the carcinogenesis of cervical cancer.
Collapse
Affiliation(s)
| | | | | | | | | | - Hua Tang
- Tianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, No, 22 Qi-Xiang-Tai Road, Tianjin 300070, China.
| |
Collapse
|
6
|
Sanchez-Martínez D, Krzywinska E, Rathore MG, Saumet A, Cornillon A, Lopez-Royuela N, Martínez-Lostao L, Ramirez-Labrada A, Lu ZY, Rossi JF, Fernández-Orth D, Escorza S, Anel A, Lecellier CH, Pardo J, Villalba M. All-trans retinoic acid (ATRA) induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity. Int J Biochem Cell Biol 2014; 49:42-52. [PMID: 24440757 DOI: 10.1016/j.biocel.2014.01.003] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2013] [Revised: 12/16/2013] [Accepted: 01/02/2014] [Indexed: 11/26/2022]
Abstract
NK cell is an innate immune system lymphocyte lineage with natural cytotoxicity. Its optimal use in the clinic requires in vitro expansion and activation. Cytokines and encounter with target cells activate NK cells and induce proliferation, and this could depend on the presence of other immune cells. Here we activated PBMCs during 5 days with IL-2, with IL-2 plus the tumor cell line K562 and with the lymphoblastoid cell line R69 and perform integrated analyses of microRNA and mRNA expression profiles of purified NK cells. The samples cluster depending on the stimuli and not on the donor, indicating that the pattern of NK cell stimulation is acutely well conserved between individuals. Regulation of mRNA expression is tighter than that of miRNA expression. All stimuli induce a common preserved genetic remodeling. In addition, encounter with target cells mainly activates pathways related to metabolism. Different target cells induce different NK cell remodeling which affects cytokine response and cytotoxicity, supporting the notion that encounter with different target cells significantly changing the activation pattern. We validate our analysis by showing that activation down regulates miR-23a, which is a negative regulator of cathepsin C (CTSC) mRNA, a gene up regulated by all stimuli. The peptidase CTSC activates the granzymes, the main effector proteases involved in NK cell cytotoxicity. All-trans retinoic acid (ATRA), which induces miR-23a expression, decreases CTSC expression and granzyme B activity leading to impaired NK cell cytotoxicity in an in vivo mouse model.
Collapse
Affiliation(s)
- Diego Sanchez-Martínez
- Cell Immunity in Cancer, Inflammation and infection Group, Biomedical Research Center of Aragon (CIBA), Nanoscience Institute of Aragon (INA), Aragon I+D Foundation (ARAID), IIS Aragon/University of Zaragoza, Zaragoza 50009, Spain
| | - Ewelina Krzywinska
- INSERM U1040, Université de Montpellier 1, UFR Médecine, Montpellier F-34295, France
| | - Moeez G Rathore
- INSERM U1040, Université de Montpellier 1, UFR Médecine, Montpellier F-34295, France
| | - Anne Saumet
- Institut de Recherche en Cancérologie de Montpellier INSERM U896, Université Montpellier 1, CRLC Val d'Aurelle Paul Lamarque, Montpellier F-34298, France
| | - Amelie Cornillon
- INSERM U1040, Université de Montpellier 1, UFR Médecine, Montpellier F-34295, France
| | - Nuria Lopez-Royuela
- INSERM U1040, Université de Montpellier 1, UFR Médecine, Montpellier F-34295, France
| | - Luis Martínez-Lostao
- Apoptosis, Immunity and Cancer Group, Department Biochemistry and Molecular and Cell Biology, Faculty of Sciences, University of Zaragoza, Zaragoza 50009, Spain
| | - Ariel Ramirez-Labrada
- Apoptosis, Immunity and Cancer Group, Department Biochemistry and Molecular and Cell Biology, Faculty of Sciences, University of Zaragoza, Zaragoza 50009, Spain
| | - Zhao-Yang Lu
- INSERM U1040, Université de Montpellier 1, UFR Médecine, Montpellier F-34295, France
| | - Jean-François Rossi
- INSERM U1040, Université de Montpellier 1, UFR Médecine, Montpellier F-34295, France
| | | | - Sergio Escorza
- Progenika Biopharma SA, Parque Tecnológico Bizkaia 504, 48160 Derio, Bizkaia, Spain
| | - Alberto Anel
- Apoptosis, Immunity and Cancer Group, Department Biochemistry and Molecular and Cell Biology, Faculty of Sciences, University of Zaragoza, Zaragoza 50009, Spain
| | - Charles-Henri Lecellier
- Institut de Génétique Moléculaire de Montpellier UMR 5535 CNRS, 1919 route de Mende, 34293 Montpellier cedex 5, France. Université Montpellier 2, Place Eugène Bataillon, 34095 Montpellier cedex 5, France. Université Montpellier 1, 5 Bd Henry IV, 34967 Montpellier Cedex 2, France
| | - Julian Pardo
- Cell Immunity in Cancer, Inflammation and infection Group, Biomedical Research Center of Aragon (CIBA), Nanoscience Institute of Aragon (INA), Aragon I+D Foundation (ARAID), IIS Aragon/University of Zaragoza, Zaragoza 50009, Spain
| | - Martin Villalba
- INSERM U1040, Université de Montpellier 1, UFR Médecine, Montpellier F-34295, France; Institut de Recherche en Biothérapie (IRB), CHU Montpellier, Montpellier 34295, France.
| |
Collapse
|